

Daftar Pustaka

1. Anwar AD, Harsono AB, Sasotya RMS, Amarullah MN, Hidayat D, editors Prinsip dasar kemoterapi BCCOG. Bandung : Sagung Seto ; 2013. p. 260.
2. Palumbo MO, Kavan P, Jr WHM, Panasci L, Assouline S, Johnson N, et al. Systemic cancer therapy : achievements and challenges that lie ahead. *Frontiers in Pharmacology*. 2013; 57(4): 1-8.
3. Bagnall-Moreau C, Chaudhry S, Salas-Ramirez K, Ahles T, Hubbard K. Chemotherapy-Induced Cognitive Impairment Is Associated with Increased Inflammation and Oxidative Damage in the Hippocampus. *Mol Neurobiol*. 2019;56(10):7159–72.
4. Elbeltagy M, Mustafa S, Umka. Fluoxetine improves the memory deficits caused by the chemotherapy agent. 2012;208:112-117
5. Taillibert S, Le Rhun E, Chamberlain MC. Chemotherapy-Related Neurotoxicity. *Curr Neurol Neurosci Rep* . 2016;16(9).
6. Gokal K, Munir F, Ahmed S, Kancherla K, Wallis D. Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial. *PLoS One*. 2018;13(11):1–23.
7. Anita dan Sukamti T. Pengaruh pemberian booklet kemoterapi terhadap kemampuan perawatan diri penderita keganasan payudara pasca kemoterapi di ruang bedah Rumah Sakit Abdul Moeloek Bandar Lampung. *Jurnal kesehatan*. 2016; 7(1): 26-33.
8. Briones TL, Woods J. Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. *BMC Neurosci*. 2011; 12(1) :124.
9. Ren X, Boriero D, Chaiswing L, Bondada S, Clair DKS, Butterfield DA. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors. *BBA - Molecular Basis of Disease*. 2019; 1865: 1088–1097
10. Muniyandi DK, Ganesan RM, Meenakshisundaram M, Palanichamy S. Effect of cancer chemotherapy on cognitive function. *Int J Cancer Res*. 2018;14(2):52–7.

11. Cheng H, Li W, Gong L, Xuan H, Huang Z, Zhao H, et al. Altered resting-state hippocampal functional networks associated with chemotherapy-induced prospective memory impairment in breast cancer survivors. *Sci Rep* . 2017;7(March):1–10.
12. World Health Organization. International agency for Research on Cancer. 2018 [cited 2019 September 20]. Available from : URL : https://www.iarc.fr/wp-content/uploads/2018/09/pr263_E.pdf
13. Definition of cancer. National Cancer Institute the U.S Government's Principal Agency for Cancer Research. 2007 [cited 2019 September 21]. Available from : URL : <http://aidsinfo.nih.gov/glossary/national-cancer-institute>.
14. Cooper GM. *The cells : A mollecular Approach*. Sunderland : Sinauer Associates. 2000.
15. Cancer. World Health Organization. 2018 [cited 2020 January]. Available from : URL : <https://www.who.int/en/news-room/fact-sheets/detail/cancer>.
16. Kementerian Kesehatan Republik Indonesia. Pusat Data dan Informasi. 2015. Available from : URL : <http://www.depkes.go.id/view/structure-publikasi-pusdatin-info-datin>.
17. International Agency for Research on Cancer. Cancer fact sheets. 2018. Available from: URL: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
18. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. *Cancer statistics. CA Cancer J Clin*. 2008; 58 (2): 71–96.
19. Cassidy J, Bissett D, Spence R. Etiology and epidemiology. In: Lyman GH. *Oxford American handbook of oncology*. 2nd ed. New York: Oxford University Press; 2015. p. 15-24.
20. Sukardja I. Biologi tumor. In: Sukardja I, *Buku onkologi klinik*. Surabaya: Airlangga University Press; 2000. p. 43-4.
21. Kartawiguna E. Faktor-faktor yang berperan pada karsinogenesis. 2001; 20(1): 16-26.
22. Peng L, Xu T, Long T, Zuo H. Association between BRCA status and P53 status in breast cancer: A meta-analysis. *Med Sci Monit*. 2016;22:1939–45.

23. Lal A, Ramazzotti D, Weng Z, Liu K, Ford JM, Sidow A. Comprehensive Genomic Characterization of Breast Tumors with BRCA1 and BRCA2 Mutations. *bioRxiv*. 2018; 1-13.
24. Sibio AD, Abriata G, buffa R, Viniegra M, Forman D, Sierra MS. etiology of breast cancer in Central and South America. IARC Scientific Publications. 2016. p. 4-8.
25. Sukardja I. Dasar-dasar kemoterapi keganasan. In: Sukardja I, Buku onkologi klinik. Surabaya: Airlangga University Press; 2000. p. 239.
26. Beattie BL. Cancer: epidemiology, patophysiology, diagnosis and management. In: Beattie BL, Michel JP, Martin FC, Walston JD. Oxford textbook of geriatric medicine. 3rd ed. New York: Oxford University Press; 2018. p. 82.
27. Ramli M. Update breast cancer management diagnostic and treatment. *Majalah Kedokteran Andalas*. 2015; 38: 28-53.
28. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: older adult oncology. 2018 [cited 2019 November 10]. Available from: URL : NCCN.org.
29. Sukardja I. Terapi polifarma. In: Sukardja I, Buku onkologi klinik. Surabaya: Airlangga University Press; 2000. p. 248.
30. American cancer society. Chemoteraphy for breast cancer. 2019 [cited 2020 Desember 20]. Avaiable from : URL : <https://amp.cancer.org/cancer/breast-cancer.html>.
31. *Moo TA, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. NHS Public Access. 2018. 13(3): 339–354.*
32. Haryono SJ, Sutandyo N, Karsono R, Karsono B, Purwanto DJ, Dien A, et al. Treatment Pattern and Safety Results of Docetaxel- (Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients in Indonesia: Part of Asia-Pacific Breast Initiative II. *Indones J Cancer*. 2019;13(1):1.
33. Jackisch C, Harbeck N, Huober J, Von Minckwitz G, Gerber B, Kreipe HH, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. *Breast Care*. 2015;10(3):211–9.

34. Ramli M. Update breast cancer management diagnostic and treatment. *Majalah Kedokteran Andalas*. 2015;38:28-53.
35. Helleday, T. Chemotherapy induced toxicity-a secondary effect cause by releasing DNA. *Annals of Oncology*. 2017; 28: 2054-2055.
36. Lian Q, Xu J, Yan S, Huang M, Ding H, Sun X, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. *Cell Res*. 2017;27(6):784–800.
37. Sharma A, Housyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. *Clin Mol Hepatol*. 2014; 20(3): 317-326.
38. Florescu M, Cinteza M, Vinereanu D. Chemotherapy induced cardiotoxicity. *Maedica (Buchar)*. 2013; 8(1): 59–67.
39. Mark N, Coruh B. Chemotherapy drug-induced lung injury. *Pulmonary Medicine*. 2017.
40. Yang M, Moon C. Neurotoxicity of cancer chemotherapy. *Neural Regen res*. 2013; 8(13): 1606-1614.
41. Castells M. Drug Hypersensitivity and anaphylaxis in cancer and chronic inflammatory disease : the role of desensitization. *Front Immunol*. 2017; 8: 1472.
42. Blumenfeld Z. Chemotherapy and fertility. *Best Pract Res Clin Obstet Gynaecol*. 2012; 26(3) :379-90.
43. Mayo Clinic. Chemo brain definition-disease and condition. 2019 [cited 2019 october 15. Available from : URL : <https://www.mayoclinic.org/diseases-conditions/chemobrain/symptoms-causes/syc-20351060>.
44. Fisher GG, Chacon M, Chaffee DS. Theories of cognitive aging and work. *Work Across the Lifespan*. Elsevier Inc.; 2019. 17–45 p.
45. Komalasari R. Domain fungsi kognitif setelah terapi stimulasi kognitif. *Jurnal Keperawatan Indonesia*. 2014; 17: 11-17
46. Harvey PD. Domains of cognition and their assessment. *Dialogues Clin Neurosci*. 2019;21(3):227–37.

47. Agelink van Rentergem JA, de Vent NR, Schmand BA, Murre JMJ, Staaks JPC, Huizenga HM. The Factor Structure of Cognitive Functioning in Cognitively Healthy Participants: a Meta-Analysis and Meta-Analysis of Individual Participant Data. *Neuropsychol Rev.* 2020;30(1):51–96.
48. Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM et al. Genetic variation in DTNBP1 influences general cognitive ability *Human Molecular Genetic.* 2006 :1563.
49. Baker LD, Barsness SM, Borson S et al. Effects of Growth Hormone–Releasing Hormone on Cognitive Function in Adults With Mild Cognitive Impairment and Healthy Older Adults: Results of a Controlled Trial. *Arch Neurol.* 2012;1420.
50. Sack I, Streitberger KJ, Krefting D, Paul F, Braun J. The influence of physiological aging and atrophy on brain viscoelastic properties in humans. *PLoS One.* 2011: 2345.
51. Rasyid IA, Syafrida Y, Sastri S. Hubungan faktor risiko dengan gangguan kognitif pada lanjut usia Kecamatan Padang Panjang Timur Kota Padang Panjang. *Jurnal Kesehatan Andalas.* 2017; 6(1).
52. Husein N, Lumenpouw S, Ramli Y, Herqutanto. Montreal cognitive assessment versi indonesia (MoCA-INA) untuk skrining gangguan fungsi kognitif. *Departemen Neurologi FKUI.* 2010; 27(4).
53. Anderson JE, Trujillo M, Mcelroy T, Groves T, Alexander T, Kiffer F, et al. Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model. *Toxicol Sci.* 2020;173(1):156–70.
54. Vichaya EG, Chiu GS, Krukowski K, Lacourt T E, Kavelaars A, Dantzer R, et al. Mechanisms of chemotherapy-induced behavioral toxicities. *Front Neurosci.* 2015; 9: 131.
55. Fardell JE, Vardy J, Shah JD, Johnston IN. Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. *Psychopharmacology (Berl).* 2012; 220(1): 183.
56. Sofis MJ, Jarmolowicz Dp, Kaplan SV, Gehringer RC, Lemley SM, Garg G, et al. KU32 prevents 5-fluorouracil induced cognitive impairment. *Behav Brain Res.* 2017; 329: 186-190.

57. Lyons L, ELBeltagy M, Bennett G, Wigmore P. The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat. *PLoS One*. 2011;6(6):1–5.
58. Zhang Q, Gao X, Liu S, Yu L, Zhu J, Qiu S. Therapies for cognitive impairment in breast cancer survivors treated with chemotherapy: A protocol for systematic review. *Medicine (Baltimore)*. 2020;99(19):e20092.
59. Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: An update on state of the art, detection, and management strategies in cancer survivors. *Ann Oncol*. 2019;30(12):1925–40.
60. Elbeltagy M, Mustafa S, Umka J, Lyon L, Salman A. Fluoxetine improves the memory deficits caused by the chemotherapy agent. 2010; 208: 112-117.
61. Hardy SJ, Krull KR, Wefel JS, Janelisins M. Cognitive change in cancers survivors. *American Society of Clinical Oncology*. 2018 [cited 2019 october 20]. Available from : URL : https://ascopubs.org/doi/10.1200/EDBK_201179
62. Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Hecke WV, et al. Longitudinal Assessment of chemotherapy induced structural changes in cerebral white matter and its correlation with impaired cognitive function. *Journal of Clinical Oncology*. 2012; 30(3): 274-281.
63. Meyer CA. How chemotherapy damage the central nervous system. *J Biol*. 2008; 7: 11
64. Shen CY, Chen VCH, Yeh DC, Huang SL, Zhang XR, Chai JW, et al. Association of functional dorsal attention network alterations with breast cancer and chemotherapy. *Sci Rep*. 2019;9(1):1–9.
65. Shi DD, Huang YH, Lai CSW, Dong CM, Ho LC, Li XY, et al. Ginsenoside Rg1 Prevents Chemotherapy-Induced Cognitive Impairment: Associations with Microglia-Mediated Cytokines, Neuroinflammation, and Neuroplasticity. *Mol Neurobiol*. 2019;56(8):5626–42.
66. Jusuf M. *Genetika I : Struktur dan Ekspresi Gen*. Jakarta: Sagung Seto. 2001

67. *Alberts B. Molecular Biology of the cell. Garland Science. 2008.*
68. Ren X, Boriero D, Chaiswing L, Bondada S, Clair DKS, Butterfield DA. Plausible biochemical mechanisms of chemotherapy-induced cognitive impairment (“chemobrain”), a condition that significantly impairs the quality of life of many cancer survivors. *BBA - Molecular Basis of Disease*. 2019; 1865: 1088–1097.
69. Pun PBL, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction, *Free Radic. Res*. 2009; 43: 348–364.
70. Branca JJV, Maresca M, Morucci G, Becatti M, Paternostro F, Gulisano M, et al. Oxaliplatin-induced blood brain barrier loosening: A new point of view on chemotherapy-induced neurotoxicity. *Oncotarget*. 2018;9(34):23426–38.
71. Asher A, Myers JS. The effect of cancer treatment on cognitive function. *Clinical Advances in Hematology and Oncology*. 2015; 13(7).
72. Fadhia N, Ulfiana E, Ismono S. hubungan fungsi kognitif dengan kemandirian dalam melakukan activities of daily living (ADL) pada lansia di UPT PSLU Pasuruan. Universitas Airlangga; 2014.
73. Mongsidi R, Tumewah R, Kembuan M. profil penurunan fungsi kognitif pada lansia di yayasan-yayasan manula di Kecamatan Kawangkoan. Universitas Sam Ratulangi; 2012.
74. Liu Z, Han X, Tian C, Chen J, Lei L, Liang Q, et al. A study on the relationship between chemotherapy-induced cognitive impairment and age patient with breast cancer. *JBUON*. 2018; 23(6): 1601-1605.
75. Kaur J, Sidhu B, Sibia R, Kaur B. prevalence of mild cognitive impairment among hospital patients aged 65 and above. *Delhi Psychiatry Journal*. 2014; 17(1) :60-64.
76. Allen DH, Myers S, Jansen CE, Ah DV. Assessment and management of cancer-and cancer treatment-related cognitive impairment. *J Nurse Pract*. 2018; 14(4): 217-224.
77. Wazqar DY. Cognitive Dysfunction and Its Predictors in Adult Patients with Cancer Receiving Chemotherapy: A Cross-Sectional Correlational Study. *J Nurs Res*. 2019;27(6):1–8.

78. Hodgson K, Hutchinson A, Wilson C, Nettelbeck T. A meta-analysis of the effect of chemotherapy on cognition in patient with cancer. *Cancer Treat Rev.* 2013; 39: 297-304.
79. Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. *Int J Mol Sci.* 2020;21(9).
80. Cerulla N, Arcusa A, Navarro JB, Garolera M, Enero C, Chico G, et al. Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study. *Breast Cancers Res Treat.* 2017: 1-9
81. Long MJ, Lee GD, Bell BK, Spangler EL, Perez EJ, Longo DL, et al. Preserved learning and memory following 5-flourouracil and cyclophosphamide treatment in rats. *NIH Public Access.* 2011; 100(1): 205-211.
82. El-Agamy SE, Abdel-Aziz AK, Esmat A, Azab SS. Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain. *Cancer Chemother Pharmacol [Internet].* 2019;84(1).

